Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of The Proposed Pegfilgrastim Biosimilar (PF-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia; Neutropenia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 15 Aug 2018 Status changed from recruiting to completed.
- 03 Jul 2018 Planned End Date changed from 29 Jul 2018 to 25 Jul 2018.
- 03 Jul 2018 Planned primary completion date changed from 29 Jul 2018 to 25 Jul 2018.